期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展 被引量：8

Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer
下载PDF
导出
摘要 靶向治疗是驱动基因阳性的晚期非小细胞肺癌重要的治疗手段之一,这个领域的治疗进展日新月异,包括新靶点的发现,新药物的问世以及靶向联合治疗方案的应用等,同时研究人员也深入地研究了各种靶向药物原发或获得性耐药机制。本综述旨在总结间变淋巴瘤激酶融合基因(anaplastic lymphoma kinase,ALK)及其他少见驱动基因阳性的非小细胞肺癌靶向治疗的新进展。 Targeted therapy was one of the major treatments in advanced non-small cell lung cancer（NSCLC） with positive driver genes. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers have also undergone deep investigation about the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. This review aimed to summarize the advanced developments of targeted therapy for anaplastic lymphoma kinase（ALK） and other rare driver genes in NSCLC.
作者 张权 张树才
机构地区 首都医科大学附属北京胸科医院肿瘤内科
出处 《中国肺癌杂志》 CAS CSCD 北大核心 2017年第1期66-72,共7页 Chinese Journal of Lung Cancer
关键词 肺肿瘤 靶向治疗 ALK Lung neoplasms Targeted therapy ALK
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

二级参考文献38

  • 1Riely GJ, Politi KA, Miller VA, et al. Update on epidermal groxah factor receptor ntations in non-small cell lung cancer [ J ], Clin Cancer Res, 2006, 12(24):7232-7241.
  • 2Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status[J]. Lung Cancer, 2010, 68(2) :198-203.
  • 3Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non- small-cell lung cancer [ J ]. J Clin Oncol, 2012, 30 ( 4 ) : 433 -440.
  • 4Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) [J]. J Thorac Oncol, 2014, 9(2):154-162.
  • 5Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[ J]. Nature, 2007, 448(7153) :561-566.
  • 6Zhang X, Zhang S, Yang X, et al. Fusion of EMLA and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression [J]. Mol Cancer, 2010, 9:188.
  • 7Zhang NN, Liu YT, Ma L, et al. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy[ J]. PLoS One, 2014, 9 ( 1 ) : e84501.
  • 8Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations[J]. J Clin Oncol, 2008, 26(15) :2442-2449.
  • 9Mitsudnmi T, Morita S, Yatabe Y, et al. Gefitlnib versus eisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WYrOG5405): an open label, randnmised phase 5 trial [ J ]. Lancet Oncol, 2010, 11 (2) : 121-128.
  • 10Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation- positive non-small-cell lung cancer (OPTIMAL, CTONG-0802 ) : a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oneol, 2011, 12 ( 8 ) : 735-742.

共引文献58

同被引文献98

引证文献8

二级引证文献49

中国肺癌杂志
2017年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部